ii

Class IIb indications for hydralazine and isosorbide dinitrate therapy for reducing the risk of HF hospitalization and reducing the risk of premature death:

- CHF + NYHA Class II - IV persisting despite treatment with ACEI and MRA and BB  + LVEF < 35%,
- CHF + NYHA Class II - IV persisting despite treatment with ARB and MRA and BB  + LVEF < 35%,
- CHF + NYHA Class II - IV persisting despite treatment with ACEI and ARB and BB  + LVEF < 35%,
- CHF + NYHA Class II - IV + LVEF < 35% + poor tolerance of ACEI + poor tolerance of ARB,
- CHF + NYHA Class II - IV persisting despite treatment with ACEI and MRA and BB + LVEF < 45% + dilated LV,
- CHF + NYHA Class II - IV persisting despite treatment with ARB and MRA and BB + LVEF < 45% + dilated LV,
- CHF + NYHA Class II - IV persisting despite treatment with ACEI and ARB and BB + LVEF < 45% + dilated LV,
- CHF + NYHA Class II - IV + LVEF < 45% + dilated LV + poor tolerance of ACEI + poor tolerance of ARB.